Forum of Clinical Oncology (Jul 2019)

Clinical and biological implications of Hippo pathway dysregulation in sarcomas

  • Kyriazoglou Anastasios,
  • Zakopoulou Roubini,
  • Zagouri Flora,
  • Bamias Aristotelis,
  • Dimopoulos Meletios Athanasios

DOI
https://doi.org/10.2478/fco-2018-0002
Journal volume & issue
Vol. 9, no. 1
pp. 11 – 16

Abstract

Read online

Sarcomas are mesenchymal malignant tumors with poor prognosis and limited treatment options. Hippo pathway is a recently discovered pathway normally involved in organ development and wound healing. Hippo signaling is often altered in solid tumors. The molecular elements of Hippo signaling include MST1/2 and LATS1/2 kinases which phosphorylate and regulate the activity of YAP and TAZ co-transcriptional activators. Hippo pathway cross-talks with several molecular pathways with known oncogenic function. In sarcomas Hippo signaling plays a pivotal role in tumorigenesis, evolution and resistance in chemotherapy regimens. Targeting Hippo pathway could potentially improve prognosis and outcome of sarcoma patients.

Keywords